SCHEDULE 13G: Sarborg Ltd Discloses 16.4% Passive Stake in Conduit Pharmaceuticals Inc.

Sarborg Ltd has filed a Schedule 13G, reporting a 16.4% passive beneficial ownership stake in Conduit Pharmaceuticals Inc. as of March 31, 2025.

Summary

• Sarborg Ltd, a company based in the Cayman Islands, has filed a Schedule 13G with the SEC.
• The filing indicates that Sarborg Ltd beneficially owns 1,853,933 shares of Common Stock in Conduit Pharmaceuticals Inc.
• This ownership represents 16.4% of the class of securities, calculated based on 11,338,523 shares of common stock outstanding as of April 21, 2025.
• Sarborg Ltd holds sole voting power and sole dispositive power over all 1,853,933 shares.
• The reporting person certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G) indicating a significant passive stake by Sarborg Ltd in Conduit Pharmaceuticals Inc. While it doesn't provide operational or financial performance details, a substantial passive investment by an institutional entity can be viewed as a neutral to slightly positive signal of confidence in the issuer.

Positives

• Sarborg Ltd, a Cayman Islands company, has acquired a significant passive stake, indicating potential confidence in Conduit Pharmaceuticals Inc.'s long-term prospects.
• The reporting person holds sole voting and dispositive power over its 1,853,933 shares, simplifying decision-making regarding this substantial block of shares.

Negatives

• The document does not contain information regarding the operational or financial performance of Conduit Pharmaceuticals Inc., limiting a comprehensive assessment of potential negatives.

Risks

• The filing is a passive investment disclosure and does not detail specific operational or financial risks of Conduit Pharmaceuticals Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance from Conduit Pharmaceuticals Inc. or Sarborg Ltd regarding the issuer's future outlook.

Management Comments

• Sarborg Ltd certified that the securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing is a disclosure of beneficial ownership and does not provide specific industry context or analysis related to the broader pharmaceutical sector.

Comparison to Industry Standards

• This document, a Schedule 13G, focuses solely on beneficial ownership disclosure and does not contain information suitable for comparison to industry standards, specific comparable companies, projects, or results.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by Sarborg Ltd provides transparency regarding the ownership structure, which can influence investor perception and potentially liquidity.

Next Steps

• The document does not specify any immediate future actions, events, or milestones for Conduit Pharmaceuticals Inc. or Sarborg Ltd beyond the reported beneficial ownership.

Key Dates

Keywords

Conduit Pharmaceuticals Inc., Sarborg Ltd, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing, pharmaceuticals